These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Blass JP; Gibson GE Rev Neurol (Paris); 1991; 147(6-7):513-25. PubMed ID: 1962057 [TBL] [Abstract][Full Text] [Related]
32. Tacrine in relation to amino acid transmitters in Alzheimer's disease. Bowen DM; Steele JE; Lowe SL; Palmer AM Adv Neurol; 1990; 51():91-6. PubMed ID: 1967197 [No Abstract] [Full Text] [Related]
33. Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Crouch PJ; Barnham KJ; Bush AI; White AR Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147 [TBL] [Abstract][Full Text] [Related]
35. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. Grossberg GT; Edwards KR; Zhao Q J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811 [TBL] [Abstract][Full Text] [Related]
36. Chronically mad as a hatter: anticholinergics and Alzheimer's disease pathology. Levey AI Ann Neurol; 2003 Aug; 54(2):144-6. PubMed ID: 12891665 [No Abstract] [Full Text] [Related]
37. [New strategies in the acute and chronic treatment of the patient with Alzheimer's dementia]. Rocco PL Minerva Med; 1996 Apr; 87(4):171-7. PubMed ID: 8700341 [No Abstract] [Full Text] [Related]
38. Alzheimer's disease: a time for cautious optimism. The Lancet Neurology Lancet Neurol; 2015 Aug; 14(8):779. PubMed ID: 26194922 [No Abstract] [Full Text] [Related]